TRANSMITTAL LETTER Docket No. 01160/1/US (PC27544) (General - Patent Pending) Timothy J. Hagen et al. ation Of: Application No. Filing Date Examiner Customer No. Group Art Unit Confirmation No. 10/623,228 July 18, 2003 Laura L. Stockton 26648 1626 2720 Title: SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF **INFLAMMATION COMMISSIONER FOR PATENTS:** Transmitted herewith is: Amendment Transmittal; Response to Notice of Non-Compliant Amendment; Itemized Postcad. in the above identified application. No additional fee is required. \boxtimes

is attached.

WARNING: Information on this form may become public. Credit card information should not be

Dated:

included on this form. Provide credit card information and authorization on PTO-2038.

The Director is hereby authorized to charge and credit Deposit Account No.

Patricia K. Fitzsimmons, Reg. No. 52,894
Pharmacia Corporation of Pfizer Inc.
P.O. Box 1027
Chesterfield, Missouri 63006
314.274.1490

A check in the amount of

Charge the amount of

Credit any overpayment.

Charge any additional fee required.Payment by credit card. Form PTO-2038 is attached.

as described below.

Partural Jan

 \boxtimes

CC:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450 Alexandria VA 22313-1450" [37 CFR 1.8(a)] on

19-1025

August 22, 2005

Signature of Person Mailing Correspondence

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

	MENT TRANSMIT	TTAL LETTER (La	rge Er	ıtity)		Docket No. 01160/1/US(PC27544)	
Application No.	Filing Date July 18, 2003	Examiner Laura L. Stockto	n	Customer N 26648	10.	Group Art Un 1626	it Confirmation No.
D 1111 Olymoria (1)	TITUTED THIOPHE AMMATION	NE CARBOXAMIDE C	СОМРО	UNDS FOR	THI	E TREATMEN	NT OF
ENT & TEARCHARD		COMMISSIONER FO	OR PATI	ENTS:			
		n the above-identified a	•	on.			
		CLAIMS AS AN	1ENDED)		.,	
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR		ER EXTRA		RATE	ADDITIONAL FEE
TOTAL CLAIMS	13 -	69 =		0	x	\$50.00	\$0.00
INDEP. CLAIMS	1 -	1 =		0	х	\$200.00	\$0.00
Multiple Dependen	t Claims (check if app	licable)					\$0.00
		TOTAL ADDITIONAL	FEE FO	R THIS AM	ENE	DMENT	\$0.00
Please cha A check in The Director communica Any ac Any ac Any ac Payment b WARNING: included o	ation or credit any ove dditional filing fees red atent application proce y credit card. Form PT Information on this	No. it to cover the filing to cover the filing do to charge payment of property and to Deposit Acquired under 37 C.F.R. essing fees under 37 C.	the folloccount 1.16. FR 1.17	owing fees a 19-1025 . redit card in	for n o	mation shou n PTO-2038.	
Patricia K. Fitzsim	mons, Reg. No. 52,894 ation of Pfizer Inc.		the Ur class r P.O. B	nited States Ponail in an envelox 1450, Alexan August 22, 2005 (Date)	ostal ope ndria	Service with su addressed to "C	e is being deposited with ufficient postage as first ommissioner for Patents, " [37 CFR 1.8(a)] on

Typed or Printed Name of Person Mailing Correspondence

AUG 25 2005 3005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I I I A STEEL	•		
APPLICANT:	Hagen et al.	GROUP ART UNIT:	1626
SERIAL NO.:	10/623,228	CONFIRMATION NO.:	2720
EXAMINER:	Stockton)	ATTORNEY DOCKET NO.:	01160/1/US (PC27544)
FILED:	July 18, 2003		,

TITLE:

SUBSTITUTED THIOPHENE CARBOXAMIDE COMPOUNDS FOR THE

TREATMENT OF INFLAMMATION

CERTIFICATE OF MAILING

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **August 22, 2005**.

inda K. Cooper

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

> August 22, 2005 (first business day after August 21, 2005)

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

Sir:

In response to the Notice of Non-Compliant Amendment of July 21, 2005, Applicants submit the following corrected Listing of Claims.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks/Arguments begin on page 15 of this paper.